Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc. | APG777 - (APEX) | Healthy volunteers, Atopic dermatitis (AD) | Phase 2 | Data Released | Subcutaneous | Immunology |
| Appili Therapeutics Inc | ATI-1801 | Cutaneous leishmaniasis | NDA Filing | Ongoing | intradermal | N/A |
| Appili Therapeutics Inc | ATI-1801 | Cutaneous leishmaniasis | NDA Filing | Ongoing | intradermal | N/A |
| Applied Therapeutics Inc. | govorestat (AT-007) - (INSPIRE) | Sorbitol Dehydrogenase Deficiency (SORD Deficiency) | Phase 3 | Data Released | oral | Genetic Disorder |
| Applied Therapeutics Inc. | AT-001 - (ARISE-HF) | Diabetic cardiomyopathy (DbCM) | Phase 3 | Ongoing | Oral | Cardiology |
| Applied Therapeutics Inc. | AT-001 - (ARISE-HF) | Diabetic cardiomyopathy (DbCM) | Phase 3 | Ongoing | Oral | Cardiology |
| Applied Therapeutics Inc. | govorestat (AT-007) - (INSPIRE) | Sorbitol Dehydrogenase Deficiency (SORD Deficiency) | Phase 3 | Data Released | oral | Genetic Disorder |
| Aprea Therapeutics Inc. | Eprenetapopt (APR-246) and VIDAZA (azacitidine) | TP53 mutant Myelodysplastic syndromes (MDS), Acute Myeloid Leukemia (AML) | Phase 2 | Trial Completed | Eprenetapopt intravenous VIDAZA subcutaneous or intravenous | Oncology |
